Today

Agents

Chat

Arena

Discover

More

App

Amylyx Pharmaceuticals Q2 EPS USD -0.39 Vs. IBES Estimate USD -0.36 - AMLX News | Rallies

Amylyx Pharmaceuticals Q2 EPS USD -0.39 Vs. IBES Estimate USD -0.36

AMLX•2026-08-06

Second-quarter results

Aug. 6 (Reuters) - Amylyx Pharmaceuticals Q2 operating expenses were USD 45.693 million.

Q2 operating income: USD -45.693 million vs. IBES estimate USD -42.3 million
Q2 net income: USD -43.423 million vs. IBES estimate USD -40 million
Q2 cash & investments: USD 250.8 million

Related News

BlackRock TCP Capital Q2 FY26 net investment income falls to $18.14 million; revenue drops to $40 million

TCPC•2026-08-06

Globalstar Q2 FY26 swings to net loss of $26.5 million; revenue falls 5% to $64.8 million

GSAT•2026-08-06

Prime Medicine Q2 FY26 net loss narrows to $42.1 million

PRME

•

2026-08-06

Madrigal Pharmaceuticals to present at Canaccord Genuity Annual Growth Conference

MDGL•2026-08-06

Weak Fed and yen is Bessent's perfect pair trade

TLT•2026-08-06